SABCS 2020 | 12-year results of anastrozole vs tamoxifen for breast cancer prevention

Ivana Sestak, PhD, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK, outlines the 12-year results of anastrozole versus tamoxifen for breast cancer prevention in postmenopausal women with hormone-receptor-positive (HR+) ductal carcinoma in situ (DCIS). The study demonstrated no significant differences in the reduction of breast cancer recurrences with anastrozole compared to tamoxifen, however, the two treatment approaches had different toxicity profiles that should be evaluated when deciding on breast cancer therapy therapies for postmenopausal women with HR+ DCIS. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).